For older adults and their clinicians, a single cardiac biomarker snapshot may be far less informative than watching how it moves over time. Tracking trajectories of a well-established heart-strain marker across three years significantly sharpens cardiovascular risk prediction in community-dwelling seniors — a finding with real implications for how often, and how aggressively, biomarker surveillance should be conducted in aging populations.
Drawing on 8,454 participants from the ASPREE trial and its observational extension ASPREE-XT — all free of prior cardiovascular disease and with a mean age of 78 at the three-year mark — researchers categorized individuals by how their N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels changed from enrollment to year three. Four trajectories emerged: persistently heart-stress-free, remission, incident heart stress, and sustained heart stress. Over a median follow-up of eight years, 818 cardiovascular events and 1,584 deaths occurred. Compared to those who remained persistently heart-stress-free, individuals in the sustained heart-stress category faced an adjusted absolute risk increase of 7.4 percentage points (95% CI: 4.8%–10.0%) for total CVD — encompassing nonfatal myocardial infarction, stroke, coronary heart disease death, and heart failure hospitalization.
NT-proBNP is already a guideline-endorsed marker for heart failure diagnosis and prognosis, but its utility as a longitudinal surveillance tool in ostensibly healthy older adults is less established. This study's strength lies in its scale, its community-dwelling (non-clinical) population, and its eight-year outcome horizon — rare in geriatric cardiovascular research. The trajectory-based framing adds genuine novelty: it suggests that the direction of change, not just a threshold crossing, carries independent prognostic weight. Limitations include the observational design, which precludes causal inference, and the predominantly white, high-functioning ASPREE cohort, limiting generalizability to more diverse or frailer populations. Whether acting on rising NT-proBNP trajectories — through intensified risk-factor management or pharmacological intervention — would translate these risk signals into mortality benefit remains an open, and important, clinical question.
